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Abstract: Retapamulin is a novel semisynthetic pleuromutilin antibiotic speciﬁ  cally designed 
for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits 
bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents 
that target the ribosome or ribosomal factors, minimizing the potential for target-speciﬁ  c cross-
resistance with other antibacterial classes in current use. In vitro studies show that retapamulin 
has high potency against the Gram-positive bacteria (Staphylococcus aureus, Streptococcus 
pyogenes, and coagulase-negative staphylococci) commonly found in skin and skin-structure 
infections (SSSIs), including S. aureus strains with resistance to agents such as macrolides, 
fusidic acid, or mupirocin, and other less common organisms associated with SSSIs, anaerobes, 
and common respiratory tract pathogens. Clinical studies have shown that twice-daily topical 
retapamulin for 5 days is comparable to 10 days of oral cephalexin in the treatment of secondarily 
infected traumatic lesions. A 1% concentration of retapamulin ointment has been approved for 
clinical use as an easily applied treatment with a short, convenient dosing regimen for impetigo. 
Given the novel mode of action, low potential for cross-resistance with established antibacterial 
agents, and high in vitro potency against many bacterial pathogens commonly recovered from 
SSSIs, retapamulin is a valuable enhancement over existing therapeutic options.
Keywords: retapamulin, traumatic skin lesions, topical antibiotic, skin infections, Staphylo-
coccus aureus
Introduction
Damage to skin integrity compromises its barrier function and allows bacteria to 
pass into the subdermal environment where the moist, warm, and nutritious condi-
tions are conducive to microbial colonization and proliferation. Traumatic skin lesions 
that can become infected include excoriations, lacerations, abrasions, and burns, as 
well as surgical sites involving incisions, sutured wounds, and skin-punch biopsies. 
Retapamulin is a new topical antibiotic that has been shown to be clinically effective 
in the management of skin and skin-structure infections (SSSIs).
Management of SSSIs
Three problems confront the clinical evaluation of patients with SSSIs: diagnosis, 
severity of infection, and the resistance patterns of pathogen-speciﬁ  c antibacterial 
agents. SSSIs have diverse causes that often reﬂ  ect the epidemiological setting. 
Establishing a detailed history is a key step towards a differential diagnosis and 
may also indicate likely etiologies. Speciﬁ  c etiological diagnosis is difﬁ  cult 
and generally unnecessary in patients with mild signs and symptoms of illness;1 
however, clinical assessment of the severity of the infection is essential. Patients 
with signs and symptoms of systemic toxicity (fever or hypothermia, tachycardia, 
and hypotension) should be investigated further for potentially severe, deep soft-
tissue infection. In addition to biochemical and hematological tests, this may involve Therapeutics and Clinical Risk Management 2009:5 42
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radiological procedures, emergency surgical exploration, 
and, if necessary, debridement for diagnostic and 
therapeutic reasons.1
Practice guidelines issued by the Infectious Diseases 
Society of America (IDSA) recommend that minor or uncom-
plicated SSSIs, such as secondarily infected traumatic lesions 
(SITLs), may be empirically treated with anti-staphylococcal 
semisynthetic penicillins, ﬁ  rst- or second-generation oral 
cephalosporins, macrolides, or clindamycin.1 For impetigo, 
topical antibiotic therapy is recommended for patients with 
a limited number of lesions.1
Reﬂ  ecting the main sources of contamination for acute 
wounds – the environment, surrounding skin, and endog-
enous sources involving mucous membranes – traumatic 
lesions are susceptible to contamination and colonization 
by a wide variety of aerobic, facultative, and anaerobic 
micro-organisms.2 Despite the established microbiological 
complexity of SSSIs, Staphylococcus aureus and β-hemolytic 
streptococci are widely viewed as common causes of a 
variety of these infections,2 with S. aureus considered to 
be the predominant pathogen associated with infected trau-
matic lesions.2 Increasing antibacterial resistance is a major 
problem in the treatment of these pathogens worldwide; the 
choice of empirical antibiotic treatment must include agents 
with activity against resistant strains.1
Antibacterial resistance among strains of S. aureus has 
increased dramatically in recent years. Resistance to penicillin is 
almost universal among S. aureus owing to β-lactamase produc-
tion, and high resistance to β-lactamase-stable β-lactams such as 
methicillin has followed with the acquisition of genes that alter 
penicillin-binding proteins, rendering the organism insusceptible 
to such β-lactams in isolates recovered from hospital as well 
as community infections.3 Community-associated methicillin-
resistant strains of S. aureus (CA-MRSA) are now reported to 
be an increasingly prevalent pathogen in SSSIs.4 A USA study 
found that CA-MRSA in SSSIs increased from 9% to 21% dur-
ing the period 2004 to 2006.5 For uncomplicated SSSIs due to 
CA-MRSA, the IDSA practice guidelines recommend systemic 
vancomycin, linezolid, clindamycin, or daptomycin as empiric 
ﬁ  rst-line agents with the use of others, such as doxycycline, 
minocycline, and trimethoprim–sulfamethoxazole, based on 
the results of susceptibility testing.1,6 Topical antimicrobial 
agents such as mupirocin are not without issues regarding 
resistance.7,8 However, the resistance pattern of S. aureus 
continues to broaden, with the emergence of CA-MRSA with 
reduced susceptibility to glycopeptide antibiotics,9 and increas-
ing resistance to mupirocin in both methicillin-resistant and 
methicillin-susceptible S. aureus.8,10
Most uncomplicated SSSIs are treated empirically, with 
antibacterial selection based on patient factors, pharmaco-
logic considerations, and the likely bacteriologic involve-
ment and antibacterial susceptibility pattern.3 Selection of 
therapy is generally empiric, and is only rarely made based 
on microbial culture and susceptibility results. Although sys-
temic antibacterial therapy is clearly essential for advancing 
infections and those that involve deeper tissues, lesions that 
show only localized signs of infection may be treated with 
topical agents.2 Topical antibiotic treatment causes fewer side 
effects, in particular systemic ones such as gastrointestinal 
side effects, in comparison with oral treatments,11 and also 
avoids the risk of resistance selection among the gut micro-
ﬂ  ora.12 Topical treatment also delivers a high antibacterial 
concentration at the site of infection with a relatively small 
amount of drug.13
A recent addition to available topical antibiotics is 
retapamulin, a novel semisynthetic pleuromutilin antibiotic 
that has a unique mode of action and potent in vitro activity 
against a wide range of pathogens, particularly Gram-positive 
cocci.14–17 An ointment formulation of 1% retapamulin 
received regulatory approval from the US Food and Drug 
Administration for the treatment of impetigo and from the 
European Medicines Agency in 2007 for the short-term 
treatment of the following superﬁ  cial skin infections: impe-
tigo and infected small lacerations, abrasions, and sutured 
wounds. Retapamulin is the ﬁ  rst new prescription topical 
antibiotic in more than 20 years.
Mode of action of retapamulin
Retapamulin exerts antibacterial activity by selective inhibi-
tion of protein synthesis through a unique interaction with 
the prokaryotic ribosome. By binding to bacterial ribosomes, 
retapamulin inhibits peptidyl transfer, blocks ribosomal P-site 
interactions, and inhibits normal ribosomal 50S subunit 
formation – three processes that are essential for protein 
synthesis. Many antibacterials that inhibit protein synthesis 
also bind to the 50S subunit and interact with the peptidyl 
transferase center; however, there are sufﬁ  cient differences 
in retapamulin’s mode of drug–ribosome interactions for 
retapamulin to be differentiated from other antibacterial 
agents. The interaction of retapamulin with the bacterial 
ribosome not only differentiates retapamulin from other 
non-pleuromutilin ribosomal inhibitors in terms of mode of 
action, but also indicates an important difference regarding 
the low potential for development of resistance and the 
excellent in vitro activity of retapamulin against isolates 
with demonstrable resistance to other agents. Target-speciﬁ  c Therapeutics and Clinical Risk Management 2009:5 43
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resistance to pleuromutilins is likely to emerge slowly 
through clinical use.18–20 No cross-resistance to retapamulin 
for subsets of organisms resistant to mupirocin, β-lactams, 
macrolides, or quinolones has been found.16,21,22
In vitro activity of retapamulin
Global surveillance program data
The in vitro activity of retapamulin against a large and diverse 
collection of clinical isolates from SSSIs has been studied in a 
global multicenter surveillance program.23 Retapamulin demon-
strated excellent in vitro activity against the key Gram-positive 
species associated with SSSIs: S. aureus, coagulase-negative 
staphylococci, and Streptococcus pyogenes.23 Minimum 
inhibitory concentrations (MIC) required to inhibit the growth 
of 50% (MIC50) of these three groups of organisms were 
0.03 to 0.06 µg/mL, and to inhibit the growth of 90% (MIC90) 
of these three groups of organisms were 0.03 to 0.12 µg/mL.23 
Retapamulin, at concentrations of 0.5 µg/mL, was inhibitory 
to all isolates tested.23 Against S. aureus, retapamulin was the 
most potent in vitro of 15 antibiotics tested, with a MIC90 value 
of 0.12 µg/mL, and 16-fold more active than fusidic acid, the 
most active of tested comparators against S. aureus. In vitro, 
retapamulin was also the most active agent against coagulase-
negative staphylococci and S. pyogenes. For coagulase-negative 
staphylococci, retapamulin was 32-fold more potent than the 
next most active agent, linezolid.23
In vitro activity of retapamulin: published 
studies
Retapamulin demonstrated favorable in vitro activity against 
anaerobes, including Propionibacterium species associated 
with acnes vulgaris, Fusobacterium species, and other anaero-
bic Gram-positive cocci,14,17,24 and respiratory tract pathogens, 
including Haemophilus inﬂ  uenzae, Streptococcus pneumoniae, 
and Moraxella catarrhalis.16 The in vitro activities of retapamu-
lin against common pathogens associated with uncomplicated 
SSSIs reported in published studies correspond well with those 
found in the global surveillance program.16,21,22,25–27 The range of 
MIC90 values reported were 0.12 to 0.25 µg/mL for S. aureus, 
0.06 to 0.25 µg/mL for coagulase-negative staphylococci, and 
0.03 to 0.06 µg/mL for S. pyogenes. The activity of retapamulin 
on bacterial bioﬁ  lms has not been determined.
In vitro activity against antibiotic 
resistant strains
The global surveillance program also showed that the high in 
vitro potency of retapamulin was maintained against isolates 
of S. aureus resistant to methicillin, macrolides, fusidic acid, 
or mupirocin with MIC90 values of 0.12 µg/mL. The most 
active comparator agent tested, fusidic acid, was 16-fold 
less active than retapamulin against drug-resistant isolates 
of S. aureus.23 The high potency of retapamulin against 
S. aureus and other organisms resistant to other antimicro-
bial agents has been conﬁ  rmed by published studies, which 
have reported MIC90 values of 0.12 µg/mL for S. aureus 
resistant to erythromycin, mupirocin, and oxacillin; 0.06 to 
0.12 µg/mL for coagulase-negative staphylococci (includ-
ing Staphylococcus epidermidis) resistant to mupirocin and 
oxacillin; and 0.03 µg/mL for S. pyogenes resistant to 
erythromycin.16,21,22 Against 664 S. aureus isolates from the 
UK, including many resistant to fusidic acid and/or highly 
resistant to mupirocin, retapamulin inhibited 663 (99.8%) 
isolates at 0.25 mg/L.28
Propensity for the development 
of resistance to retapamulin in vitro
The distinct interaction between pleuromutilins and the 50S 
ribosome distinguishes their mode of action from those of 
other classes of antibiotics. This unique mode of action 
minimizes the potential for target-speciﬁ  c cross-resistance 
with other antibacterial classes in current use. This has been 
demonstrated through the ﬁ  nding that retapamulin is active in 
vitro against clinical isolates that are resistant to many other 
classes of antibiotics that act by inhibiting protein synthe-
sis. Retapamulin also has activity against isolates resistant 
to antibiotics with very different modes of action, such as 
β-lactams and quinolones. Extensive preclinical testing has 
shown that retapamulin has a slow and gradual propensity for 
resistance development in S. aureus and a low potential for 
resistance selection in S. pyogenes.19,20 In multi-step passage 
studies, increased MIC values to retapamulin were seen 
among isolates of S. aureus and S. pyogenes, but required 
more passages and occurred at a lower magnitude compared 
with mupirocin or fusidic acid (Figure 1). Furthermore, 
retapamulin had the lowest MIC values among the drugs 
tested.19 This low potential for resistance selection limits 
concerns with regard to pathogens developing resistance to 
retapamulin through clinical use, which is a known problem 
with other topical antibiotics (eg, resistance to mupirocin or 
fusidic acid in S. aureus).8,29
Efﬁ  cacy of retapamulin in SITLs
The efﬁ  cacy, safety, and tolerability of topical retapamulin 
ointment, 1%, was demonstrated in two identical, randomized, 
double-blind, double-dummy, active-controlled, multicenter Therapeutics and Clinical Risk Management 2009:5 44
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studies in 1904 patients with SITLs. In these studies, the 
clinical efﬁ  cacy of retapamulin was high and comparable 
to that of cephalexin. Using a prespeciﬁ  ed non-inferiority 
margin of 10%, retapamulin ointment, 1%, applied twice daily 
for 5 days, was shown to be non-inferior to oral cephalexin, 
500 mg, twice daily for 10 days in both studies.30 In the 
per-protocol (PP) analyses, the pooled clinical success rates 
at follow-up (7–9 days post-therapy) were 89.5% in patients 
receiving retapamulin, compared with 91.9% for patients 
treated with cephalexin (treatment difference: −2.5%; 95% 
confidence interval [CI]: −5.4%, 0.5%) (Figure 2).30 In 
patients with S. aureus or S. pyogenes at baseline, clinical 
success rates at follow-up for patients treated with retapamulin 
and cephalexin were 89.2% (365/409) and 92.6% (63/68), 
respectively.
Retapamulin treatment was successful in the small 
numbers of patients with SITLs due to fusidic acid- or 
mupirocin-resistant strains of S. aureus (clinical success 
rates of 11/12 and 6/7, respectively [intent-to-treat (ITT) 
bacteriologic population]).32 Against MRSA, clinical 
success was achieved by treatment with retapamulin in 37 of 
57 isolates (64.9%) and by cephalexin treatment in 27 of 
33 isolates (81.8%) (ITT bacteriologic population).32 In 
these studies, SITLs included abrasions, lacerations, sutured 
wounds, and simple abscesses. If patients with abscesses were 
excluded, the clinical success rate against MRSA was 75.7% 
(28/37) in retapamulin-treated patients and 80.8% (21/26) in 
cephalexin-treated patients.33
Safety and tolerability were similar for the two treat-
ments (see ‘Safety and tolerability’ section below for more 
details). Non-compliance, deﬁ  ned as taking <80% of doses, 
was recorded in 8.0% (51/636) of patients receiving cepha-
lexin, compared with 0.4% (5/1268) of patients receiving 
retapamulin.30
Retapamulin for the treatment 
of secondarily infected dermatitis
In another randomized, double-blind, active-controlled study, 
the clinical efﬁ  cacy and safety of topical retapamulin was 
compared with oral cephalexin for the treatment of secondarily 
infected dermatitis (SID), which included subjects with an 
underlying skin disease such as atopic dermatitis, psoriasis, 
Figure 1 In multi-step studies, increased minimum inhibitory concentrations (MICs) to retapamulin were seen among Staphylococcus aureus isolates, but required more passages 
compared with mupirocin or fusidic acid; ﬁ  gure shows a summary of the 12 S. aureus isolates tested. Drawn from data of Kosowska-Shick et al.19Therapeutics and Clinical Risk Management 2009:5 45
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or allergic contact dermatitis that had a secondary bacterial 
infection.31 In this study, patients with SID were randomly 
assigned to treatment with retapamulin ointment, 1%, twice 
daily for 5 days, or oral cephalexin, 500 mg, twice daily for 
10 days. At the follow-up visit (7–9 days post therapy) in 
the PP clinical population, the efﬁ  cacy of retapamulin was 
comparable to that of cephalexin, with clinical success rates 
of 85.9% and 89.7%, respectively (treatment difference: 
–3.8%; 95% CI: –9.9%, 2.3%). Microbiologic success rates at 
follow-up were 87.2% for retapamulin and 91.8% for cepha-
lexin. Retapamulin treatment was generally effective against 
the small numbers of fusidic acid-, methicillin-, or mupirocin-
resistant S. aureus isolates (clinical success rates of 3/5, 5/5 and 
4/5, respectively, in the PP bacteriological population).32
Retapamulin for the treatment 
of impetigo
In the treatment of impetigo, retapamulin was compared with 
placebo in a randomized, double-blind, multicenter study in 
213 patients who received either topical retapamulin or placebo 
ointment, twice daily for 5 days.34 Based on the primary efﬁ  cacy 
endpoint of clinical response at the end of therapy visit (day 
2 post-therapy) in the ITT clinical population, retapamulin 
ointment was superior to placebo (success rate 85.6% vs 
52.1%; p < 0.0001). Similar results were found in the PP 
clinical population and for those patients in the bacteriological 
population who had had a pathogen isolated at baseline.34
In another clinical study, retapamulin, twice daily for 
5 days, was compared with 2% fusidic acid ointment, three 
times daily for 7 days, in 519 adult and pediatric patients 
(aged at least 9 months) with impetigo.35 In the PP clinical 
population, the clinical success rates at the end of therapy with 
retapamulin and fusidic acid were 99.1% and 94%, respec-
tively (difference 5.1%, 95% CI: 1.1%, 9.0%, p = 0.003). In 
the ITT clinical population, clinical success rates at the end 
of therapy with retapamulin and fusidic acid were 94.8% and 
90.1%, respectively (difference: 4.7%, 95% CI: –0.4%, 9.7%, 
p = 0.062).35 In the analysis of patients who had a pathogen 
isolated at baseline, the bacteriologic efﬁ  cacy of retapamulin 
was superior in both the PP and ITT populations. Retapamulin 
treatment was successful in the few fusidic acid-, methicillin-, 
or mupirocin-resistant isolates of S. aureus (clinical success 
rates of 9/9, 8/8, and 6/6, respectively).35
Safety and tolerability 
of retapamulin in SSSIs
Phase III trials in the retapamulin clinical development program, 
in which 2115 patients received retapamulin, demonstrated the 
safety of this new antibacterial agent in patients with SITLs, 
SID, and impetigo.30,31,36–38 An adverse event (AE) was deﬁ  ned 
Figure 2 Clinical success rates at follow-up in the per-protocol clinical populations from randomized controlled clinical trials comparing topical retapamulin, 1%, twice daily 
for 5 days, with placebo in the treatment of impetigo and oral cephalexin, 500 mg, twice daily for 10 days, in the treatment of secondarily infected traumatic lesions (SITLs) 
and secondarily infected dermatitis (SID). Drawn from data of Koning et al,11 Free et al,30 and Parish et al.31Therapeutics and Clinical Risk Management 2009:5 46
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as any untoward medical occurrence that was temporally 
associated with the use of a medicinal product, whether or not 
it was considered by the investigator to be related to the use of 
that medicinal product.
The frequency of AEs of any type was low in patients 
receiving retapamulin, with a broadly similar incidence 
across studies and treatment groups.39 Overall, the frequency 
of occurrence of all AEs varied little across age groups in 
patients receiving retapamulin. The majority of AEs were 
of mild or moderate intensity; AEs of severe intensity were 
reported by 28 (1.3%) patients across retapamulin groups in 
all studies. Serious AEs were reported by 0.5% of patients 
(11/2115) treated with retapamulin, none of which were 
considered by the investigator to be related to treatment. The 
most common AEs for retapamulin were application-site 
reactions; these occurred in 2.6% (56/2115) of patients for 
retapamulin, 0.9% (7/819) of patients for cephalexin, and 
4.2% (3/71) of patients for placebo. Across all studies, very 
few patients treated with retapamulin withdrew because of 
an AE (1.2%, 26/2115).39
The frequencies of AEs that were considered by the 
investigator to be related to use of the study medication 
were 5.5% (116/2115) for retapamulin, 6.6% (54/819) 
for cephalexin, 0.6% (1/172) for fusidic acid, and 2.8% 
(2/71) for placebo.40 Across all studies, the only individual 
treatment-related AEs that were reported in at least 1% of 
patients were application-site irritation (1.4% [29/2115]) 
in the retapamulin group and diarrhea (1.7% [14/819]) in 
patients receiving cephalexin.40
In the SITL treatment studies, the overall rates of 
AEs were comparable: 22.8% (289/1268) of patients who 
received retapamulin and 25.3% (161/636) of patients 
in the cephalexin group reported one or more AEs. The 
incidence of all treatment-related AEs was 5.3% (67/1268) 
in the retapamulin group and 7.7% (49/636) in the cepha-
lexin group. The most common treatment-related AEs 
were application-site irritation (1.3% [17/1268]) in those 
who received retapamulin, and diarrhea (1.9% [12/636]) 
and nausea (1.6% [10/636]) in patients treated with 
cephalexin.30
There were no notable changes in laboratory values 
obtained from routine hematology and clinical chemistry 
tests over the study period in patients randomly assigned to 
retapamulin in any of the clinical trials. Furthermore, for all 
laboratory clinical values, there were no large mean changes 
from baseline for the total retapamulin population. Across 
all treatment groups there were no notable changes in any 
of the age groups.39
As with all topical antibiotics, application of retapamulin 
ointment directly on the infected area minimizes the likeli-
hood of generalized AEs, such as gastrointestinal distur-
bances, that can occur with oral antibiotics.11,12,41 In adult 
patients with SITLs treated with retapamulin, twice daily for 
5 days, measurable plasma concentrations of the drug were 
detected in only 47 of 380 samples (range, 0.52–10.7 ng/mL). 
In children, measurable plasma concentrations were detected 
in only 9 of 136 samples (range, 0.54–18.5 ng/mL).36
Patient preference and compliance
As with other therapeutic regimens, patient compliance 
is essential in the effectiveness of prescribed antibiotics. 
With poor compliance, therapeutic goals are less likely to 
be achieved, resulting in poorer patient outcomes.42–44 Poor 
compliance is associated with deteriorating health, the need for 
additional consultations, the emergence of bacterial resistance, 
extra drugs, additional hospital admissions, and increases in 
direct and indirect costs of healthcare management.44–46
In general, patients are more compliant with simple and 
less-frequent dosing regimens. Both the dosage schedule 
and the patient’s daily routine should be considered when 
prescribing antibiotics.47 Topical agents may also be more 
attractive than oral therapy because they reduce the potential 
for systemic side effects, typically nausea and diarrhea, which 
are commonly associated with many systemic antibiotics.12
Throughout the phase III clinical trial program for 
retapamulin, compliance was measured using diary cards that 
patients or their parents or guardians had completed. If doses 
were missed, the patient would have attained less than 100% 
compliance; if more treatment had been used than instructed, 
the patient would have exceeded 100% compliance. Taking 
the capsules/suspension or using the ointment within 80% 
to 120% of the desired dose was deﬁ  ned as compliance with 
treatment.
In the SITL clinical trials, compliance with the retapamulin 
regimen was greater than that for cephalexin (Figure 3). In the 
ITT clinical population, 8.0% (51/636) of patients taking oral 
cephalexin took <80% of the prescribed dose, compared with 
0.4% (5/1268) of patients applying retapamulin ointment.30 
In the SID study, compliance was similar for the two 
treatment arms.31 Patients with SID were asked during their 
end-of-treatment visit whether they preferred oral or topical 
therapy, or had no preference for treatment. The majority of 
patients in each treatment group (60.6% and 56.8% in the 
retapamulin and cephalexin groups, respectively) preferred 
topical medication. Oral medication was preferred by fewer 
than 20% of patients in both treatment groups (Figure 4).31 Therapeutics and Clinical Risk Management 2009:5 47
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The shorter treatment course for retapamulin compared with 
cephalexin – 5 days versus 10 days – may have inﬂ  uenced treat-
ment preference. These results suggest that there is a preference 
for topical over oral antibacterial therapy for the treatment of 
SSSIs, a conclusion that has been reported by others.48,49
The ease of application and short, convenient dosing 
regimen of retapamulin is conducive to good compliance.31 In 
clinical practice, patients are expected to beneﬁ  t from the shorter 
duration of treatment and lower overall dosing frequency of 
retapamulin compared with other topical or oral antibiotics, as 
shorter treatment regimens and less frequent dosing are gener-
ally associated with improved compliance, patient preference, 
or both.31,42,43 A short, convenient dosing regimen also reduces 
the potential for treatment failure and minimizes the develop-
ment of antibacterial drug resistance.31
Conclusions
Antibacterial resistance against many pathogens and several 
classes of antibacterial agents has increased markedly in 
recent years. This is clearly seen among the many bacterial 
species common to infected traumatic lesions, and with 
S. aureus in particular. Antibacterial resistance patterns are 
changing and should be taken into account in the choice of 
therapy. Topical antibiotic ointments are an effective treat-
ment option for patients with limited or uncomplicated SSSIs, 
including SITLs.1,6 Topical agents may be more attractive than 
oral therapy because they reduce the potential for systemic 
side effects, such as nausea and diarrhea, and avoid resistance 
selection in the gut ﬂ  ora. In addition, application of the anti-
biotic directly to the infected lesion may result in higher local 
concentrations at the site of infection and, consequently, allow 
overall use of the drug to be reduced.12 For uncomplicated skin 
infections not requiring systemic antimicrobial therapy, such 
as impetigo, SITLs, and SID, a topical antibiotic should ideally 
have a sufﬁ  ciently broad spectrum of activity to be used as 
monotherapy, must not promote cross-resistance, and should 
be well tolerated with a low potential for AEs.
Retapamulin, the ﬁ  rst new topical antibiotic in more than 
20 years, has potent in vitro antibacterial activity against the 
most likely pathogens causing uncomplicated skin infections. 
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Figure 3 Compliance with retapamulin was greater than that for cephalexin in patients with secondarily infected traumatic lesions treated with topical retapamulin, 1%, twice 
daily for 5 days, or with oral cephalexin, 500 mg, twice daily for 10 days; ﬁ  gure shows pooled data from two identical randomized controlled clinical trials (Study 030A and 
030B) for intent-to-treat patients who were 80%–120% compliant with study treatment.30 For secondarily infected dermatitis (Study 032), there was no difference in compliance 
between the two treatment arms.31 Patients 13 years of age received cephalexin capsules; those who were younger received cephalexin suspension. Drawn from data of 
GlaxoSmithKline.36Therapeutics and Clinical Risk Management 2009:5 48
Shawar et al
Retapamulin has a unique mode of action that differentiates it 
from other non-pleuromutilin antibacterial agents that target 
bacterial protein synthesis, and minimizes the potential for 
target-speciﬁ  c cross-resistance with other antibacterial classes 
in current use. Topical treatment with retapamulin, twice daily 
for 5 days, has been shown in studies of impetigo to be superior 
to placebo, and in studies of SITLs and SID to be comparable to 
10 days of oral cephalexin. Retapamulin offers a novel, effective, 
and convenient topical treatment for uncomplicated SSSIs.
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